^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lymphoplasmacytic Lymphoma

    Related cancers:
    2d
    Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) (clinicaltrials.gov)
    P2, N=14, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax)
    3d
    A case report of lymphoplasmacytic lymphoma with spherocytosis. (PubMed, Open Life Sci)
    The patient's condition stabilized following targeted therapy with zanubrutinib and rituximab (ZR regimen). This case underscores the complexity of diagnosing dual hematological anomalies, highlights the importance of multidisciplinary collaboration, and seeks to explore the potential pathophysiological link between LPL and spherocytosis, offering a reference for diagnosis and treatment in similar clinical scenarios.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib)
    3d
    Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma (clinicaltrials.gov)
    P1/2, N=180, Recruiting, ModeX Therapeutics, An OPKO Health Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    4d
    LOXO-BCL-20001: Study of Oral LOXO-338 in Patients With Advanced Blood Cancers (clinicaltrials.gov)
    P1, N=316, Active, not recruiting, Eli Lilly and Company | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    Chr t(11;14)
    |
    Jaypirca (pirtobrutinib) • FCN-338
    7d
    Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date • Adverse events
    7d
    Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (clinicaltrials.gov)
    P2, N=60, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Jan 2028 --> Mar 2029 | Trial primary completion date: Feb 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    cyclophosphamide • fludarabine IV • busulfan • cyclosporin A microemulsion • Grafapex (treosulfan) • Neupogen (filgrastim)
    11d
    PRAME: Spanish Registry of Patients With IgM Monoclonal Gammopathies (clinicaltrials.gov)
    P=N/A, N=1000, Recruiting, Fundación Española de Hematología y Hemoterapía | Trial completion date: Mar 2025 --> Mar 2030 | Trial primary completion date: Mar 2025 --> Mar 2030
    Trial completion date • Trial primary completion date
    12d
    Clinical Characteristics and Treatment Outcomes of Patients with Waldenstrom Macroglobulinemia. (PubMed, Indian J Hematol Blood Transfus)
    Most common chemo-immunotherapy was Bendamustine-Rituximab followed by Rituximab-Cyclophosphamide-Dexamethasone. The median Event-free Survival, Time to Next therapy and Overall Survival were 45 months, 51 months and 150 months respectively. In our WM case series from India, we found a low incidence of MYD88 mutations with comparable treatment outcomes to western literature.
    Journal • IO biomarker
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    |
    Rituxan (rituximab) • cyclophosphamide • bendamustine
    14d
    A Study of APG-3288 in Relapsed/Refractory Blood Cancers (clinicaltrials.gov)
    P1, N=180, Not yet recruiting, Ascentage Pharma Group Inc.
    New P1 trial
    15d
    ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia (clinicaltrials.gov)
    P1/2, N=38, Not yet recruiting, Mayo Clinic
    New P1/2 trial
    |
    etentamig intravenous (ABBV-383 IV)
    17d
    Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia (clinicaltrials.gov)
    P2, N=21, Terminated, Mayo Clinic | Trial completion date: Jun 2025 --> Jan 2026
    Trial completion date
    |
    Imbruvica (ibrutinib) • Ninlaro (ixazomib)
    17d
    MAZ-01: Zanubritnib and anti-MAG neuropathy (2025-523091-23-00)
    P1/2, N=50, Not yet recruiting, Azienda Ospedaliera di Padova
    New P1/2 trial
    |
    Brukinsa (zanubrutinib)